Skye Bioscience, Inc. Proceeds from Sale of Notes Receivable
Skye Bioscience, Inc. (SKYE) reported Proceeds from Sale of Notes Receivable of $9.57 thousand for the 9-month period ending 2013-07-31, per its 10-Q filed 2013-09-16.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfNotesReceivable · last filed 2013-09-16
- Skye Bioscience, Inc. proceeds from sale of notes receivable for the quarter ending 2013-07-31 was $0.00, a 100.00% decline year-over-year.
- Skye Bioscience, Inc. proceeds from sale of notes receivable for the quarter ending 2012-07-31 was $652.00.
| Period end | Proceeds from Sale of Notes Receivable 3 month | Proceeds from Sale of Notes Receivable 6 month | Proceeds from Sale of Notes Receivable 9 month |
|---|---|---|---|
| 2013-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-09-16 | $9.57K 10-Q · filed 2013-09-16 | |
| 2013-04-30 | $9.57K 10-Q · filed 2013-06-27 | ||
| 2012-07-31 | $652.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-09-16 | $2.60K 10-Q · filed 2013-09-16 | |
| 2012-04-30 | $1.95K 10-Q · filed 2013-06-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |